Interactive Features

Quiz

Efficacy of Rituximab Maintenance After ASCT Among Patients With Mantle Cell Lymphoma

07/09/2024

True or False: According to a 7.5-year follow-up of the LYMA trial, standard-of-care therapy of rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among...

True or False: According to a...

07/09/2024

Lymphoma, Leukemia & Myeloma Network

Quiz

Overall Response Rate of Tafasitamab Plus Lenalidomide for Patients With R/R Diffuse Large B-Cell Lymphoma

06/14/2023

Quiz: According to final results of the phase 2 L-MIND study, what was the overall response rate of tafasitamab plus lenalidomide followed by long-term tafasitamab monotherapy for patients with R/R diffuse large B-cell lymphoma?

Quiz: According to final results...

06/14/2023

Oncology

Quiz

Radiomics Features and Prediction of Outcomes for Aggressive B-Cell Lymphoma

06/09/2023

True or False In a study assessing the predictive quality of clinical, molecular genotype, and radiomics features for aggressive B-cell lymphoma, results indicated that radiomics features extracted from baseline 18F-FDG PET/CT scans...

True or False In a study...

06/09/2023

Oncology

In the News

News

Venetoclax-Ibrutinib Demonstrates Long-Term Efficacy Among Patients With R/R Mantle Cell Lymphoma

09/05/2024

Amber Denham ;

Combination venetoclax-ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma demonstrated durable responses and an acceptable toxicity profile, according to 7-year outcomes from the AIM clinical trial.

Combination venetoclax-ibrutinib...

09/05/2024

Lymphoma, Leukemia & Myeloma Network

News

Reduction of Specialized Follow-Ups for Patients With Asymptomatic and Low-to-Intermediate Risk CLL

09/04/2024

Amber Denham ;

Study results demonstrated feasibility and safety among a subset of patients with chronic lymphocytic leukemia (CLL) who have low-to-intermediate risk CLL International Prognostic Index and CLL without need of treatment scores who ended...

Study results demonstrated...

09/04/2024

Lymphoma, Leukemia & Myeloma Network

News

Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL

07/10/2024

According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...

According to phase 3b results...

07/10/2024

Lymphoma, Leukemia & Myeloma Network

News

FDA Approval of Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma

07/09/2024

The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.

The U.S. Food and Drug...

07/09/2024

Lymphoma, Leukemia & Myeloma Network

News

Circulating Tumor DNA Monitoring for Patients With Follicular Lymphoma Undergoing CAR T-Cell Therapy

06/26/2023

Jordan Kadish ;

Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.

Circulating tumor DNA monitoring...

06/26/2023

Oncology

News

Efficacy and Safety of Rituximab-Bendamustine vs R-CHOP Among Patients With Follicular Lymphoma

06/26/2023

Jordan Kadish ;

Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.

Rituximab-bendamustine and...

06/26/2023

Oncology

News

FDA Grants Accelerated Approval to Glofitamab for Patients With R/R Diffuse Large B-Cell Lymphoma

06/23/2023

Jordan Kadish ;

On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...

On June 15, 2023, the FDA...

06/23/2023

Oncology

News

Brentuximab Vedotin Plus Doxorubicin and Dacarbazine for Patients With Nonbulky Limited-Stage Classic Hodgkin Lymphoma

06/23/2023

Jordan Kadish ;

Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.

Results from a phase 2 study...

06/23/2023

Oncology

News

Clinical Outcomes After BTK Inhibitor and B-Cell Lymphoma 2 Inhibitor Treatment Among Patients With CLL

06/08/2023

Jordan Kadish ;

The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...

The real-world response rates...

06/08/2023

Oncology

News

Ki67 Expression Shows Promise as a Predictive Marker for Follicular Lymphoma

06/08/2023

Jordan Kadish ;

High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.

High follicular Ki67 expression...

06/08/2023

Oncology

Latest Podcasts

Podcasts

Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress

10/19/2020

John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.

John Leonard, MD, discusses what...

10/19/2020

Oncology

Podcasts

What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress

08/24/2020

James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.

James B. Bussel, MD, gives an...

08/24/2020

Oncology

Podcasts

Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population

06/19/2018

Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.

Todd Cooper, DO, discusses a new...

06/19/2018

Oncology

Interactive Features

In the News

Latest Podcasts

Specialties

Events

Year Round Education

HMP Global Products